Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 311

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Pooled analysis of the accuracy of five cervical cancer screening tests assessed in eleven studies in Africa and India

Open access
Arbyn, Marc, Sankaranarayanan, Rengaswamy, Muwonge, Richard, Keita, Namory, Dolo, Amadou, Mbalawa, Charles Gombe, Nouhou, Hassan, Sakande, Boblewende, Wesley, Ramani, Somanathan, Thara, Sharma, Anjali, Shastri, Surendra, Basu, Parthasarathy·2008·International Journal of Cancer

Abstract

Cervical cancer is the main cancer among women in sub‐Saharan Africa, India and other parts of the developing world. Evaluation of screening performance of effective, feasible and affordable early detection and management methods is a public health priority. Five screening methods, naked eye visual inspection of the cervix uteri after application of diluted acetic acid (VIA), or Lugol's iodine (VILI) or with a magnifying device (VIAM), the Pap smear and human papillomavirus testing with the high‐risk probe of the Hybrid Capture‐2 assay (HC2), were evaluated in 11 studies in India and Africa. More than 58,000 women, aged 25–64 years, were tested with 2–5 screening tests and outcome verification was done on all women independent of the screen test results. The outcome was presence or absence of cervical intraepithelial neoplasia (CIN) of different degrees or invasive cervical cancer. Verification was based on colposcopy and histological interpretation of colposcopy‐directed biopsies. Negative colposcopy was accepted as a truly negative outcome. VIA showed a sensitivity of 79% (95% CI 73–85%) and 83% (95% CI 77–89%), and a specificity of 85% (95% CI 81–89%) and 84% (95% CI 80–88%) for the outcomes CIN2+ or CIN3+, respectively. VILI was on average 10% more sensitive and equally specific. VIAM showed similar results as VIA. The Pap smear showed lowest sensitivity, even at the lowest cutoff of atypical squamous cells of undetermined significance (57%; 95% CI 38–76%) for CIN2+ but the specificity was rather high (93%; 95% CI 89–97%). The HC2‐assay showed a sensitivity for CIN2+ of 62% (95% CI 56–68%) and a specificity of 94% (95% CI 92–95%). Substantial interstudy variation was observed in the accuracy of the visual screening methods. Accuracy of visual methods and cytology increased over time, whereas performance of HC2 was constant. Results of visual tests and colposcopy were highly correlated. This study was the largest ever done that evaluates the cross‐sectional accuracy of screening tests for cervical cancer precursors in developing countries. The merit of the study was that all screened subjects were submitted to confirmatory investigations avoiding to verification bias. A major finding was the consistently higher sensitivity but equal specificity of VILI compared with VIA. Nevertheless, some caution is warranted in the interpretation of observed accuracy measures, since a certain degree of gold standard misclassification cannot be excluded. Because of the correlation between visual screening tests and colposcopy and a certain degree of over‐diagnosis of apparent CIN2+ by study pathologists, it is possible that both sensitivity and specificity of VIA and VILI were overestimated. Gold standard verification error could also explain the surprisingly low sensitivity of HC2, which contrasts with findings from other studies. © 2008 Wiley‐Liss, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.23489

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 311

Metadata

Authors
Arbyn, M., Sankaranarayanan, R., Muwonge, R., Keita, N., Dolo, A., Mbalawa, C. G., Nouhou, H., Sakande, B., Wesley, R., Somanathan, T., Sharma, A., Shastri, S., & Basu, P.
Venue
International Journal of Cancer
Publisher
Wiley
Published
2008-04-24
Volume
123
Issue
1
Pages
153-160
ISSN
  • 0020-7136 (ISSN-L)
  • 1097-0215
OpenAlex
W2097457622
Cited by
311
References
45
FWCI
12.48
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.